When something goes wrong with an AI assistant, our instinct is to ask it directly: "What happened?" or "Why did you do that?

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. 10 stocks we like better than Recursion Pharmaceuticals ...

It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.

Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding unexpectedly well to treatment.

Recursion Pharmaceuticals is a clinical-stage TechBio company that leverages artificial intelligence (AI), automation, and experimental biology to accelerate the discovery and development of new ...

Ray further emphasized that REC-3565, currently in Phase 1 trials and developed using Recursion’s advanced AI platform, would not have been conceived through traditional human design methods.

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) fell this week. The move comes as the S&P 500 and Nasdaq Composite both slipped slightly. Recursion revealed disappointing first-quarter earnings ...

Recursion Pharmaceuticals stock isn't a good fit for risk-averse investors. The company remains unprofitable and is losing more money as it ramps up clinical development of several candidates.

Key Points Recursion Pharmaceuticals' stock jumped after the FDA announced plans to replace the use of animals in drug testing. Recursion is a leader in AI-powered drug discovery and development.

We recently published a list of 10 Firms Kick Off Monday Leading Gains. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.